Alector (ALEC) Liabilities and Shareholders Equity (2018 - 2026)
Alector's (ALEC) quarterly Liabilities and Shareholders Equity came in at $202.9 million in Q2 2026, down 43.09% year-over-year from $356.4 million in Q2 2025, and down 15.45% quarter-over-quarter from $239.9 million in Q1 2026.
Analysis
Alector (ALEC) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $202.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Liabilities and Shareholders Equity fell 43.09% year-over-year to $202.9 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 38.75% decrease from a year earlier, with the FY2025 full-year figure at $293.2 million, down 37.38% from the prior year.
- Liabilities and Shareholders Equity was $202.9 million for Q2 2026 at Alector, down from $239.9 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $954.5 million in Q1 2022 and troughed at $202.9 million in Q2 2026.
- A 5-year average of $569.3 million and a median of $596.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity surged 124.03% in 2022 and tumbled 43.09% in 2026, its largest moves.
- Over 5 years, Liabilities and Shareholders Equity stood at $787.6 million in 2022, then dropped by 21.05% to $621.8 million in 2023, then retreated by 24.69% to $468.3 million in 2024, then slumped by 37.38% to $293.2 million in 2025, then plunged by 30.82% to $202.9 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $202.9 million (Q2 2026), $239.9 million (Q1 2026), and $293.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 95.64 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 49.36 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 27.42 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 41.73 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 10.03 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 10.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 5.56 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 32.09 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | 202.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 202.86 Mn |
| Mar 31, 2026 | 239.92 Mn |
| Dec 31, 2025 | 293.24 Mn |
| Sep 30, 2025 | 335.29 Mn |
| Jun 30, 2025 | 356.42 Mn |
| Mar 31, 2025 | 408.30 Mn |
| Dec 31, 2024 | 468.30 Mn |
| Sep 30, 2024 | 516.02 Mn |
| Jun 30, 2024 | 570.73 Mn |
| Mar 31, 2024 | 635.49 Mn |
| Dec 31, 2023 | 621.83 Mn |
| Sep 30, 2023 | 672.40 Mn |
| Jun 30, 2023 | 708.74 Mn |
| Mar 31, 2023 | 748.34 Mn |
| Dec 31, 2022 | 787.65 Mn |
| Sep 30, 2022 | 837.04 Mn |
| Jun 30, 2022 | 889.67 Mn |
| Mar 31, 2022 | 954.46 Mn |
| Dec 31, 2021 | 814.66 Mn |
| Sep 30, 2021 | 854.23 Mn |